CDC Report Reveals Low Uptake of HIV Prevention Drug PrEP Among Americans

Pre-exposure prophylaxis (PrEP) has been hailed as a highly effective drug in preventing HIV infection through sexual contact when taken as prescribed. However, a recent report by the Centers for Disease Control and Prevention (CDC) has revealed that only about one-third of the estimated 1.2 million Americans who could benefit from PrEP are currently taking advantage of it. One individual who shared her experience with PrEP is LaTonia Wilkins, who admitted to not knowing about the drug until years after an HIV scare. She also mentioned a prevailing misconception that PrEP was only meant for gay men or transgender women. Dr. Céline Gounder highlighted that individuals at risk for HIV who may benefit from PrEP include those engaging in unprotected sex with HIV-positive partners, having multiple sexual partners who are untested for HIV, or having had a sexually transmitted disease (STD) in the past six months. Data shows significant disparities in PrEP usage, with higher rates among White individuals compared to Black and Hispanic/Latino populations. Additionally, women at risk for HIV are significantly underrepresented in those currently using PrEP. Accessibility challenges for PrEP are also a concern, with the total cost of medication, clinic visits, and lab tests averaging over $5,000 annually. The landscape for PrEP access faces further challenges due to a federal court case, potential changes in insurance coverage, and proposed cuts to funding for HIV prevention programs. Initiatives like Sister Love in Atlanta are emphasizing the importance of normalizing conversations around sex and HIV to address disparities in PrEP usage. In other news, the CDC has announced updated guidance on measles vaccination for travelers and highlighted cybersecurity issues in healthcare providers. The importance of raising awareness about the benefits of PrEP, addressing disparities in its usage, and ensuring its accessibility to all who may benefit from it remains a critical focus in the fight against HIV/AIDS.